WARN : Please note that some of the values may not be in base currency

Fundamental Analysis of Atara Biotherapeutics Inc - Growth / Value Index


ATRA - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.00
   Book Value in last 3 years is trending down
   Book value is negative
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -0.347 -0.259 18.32 %
Price to Book -2.30 -0.758 -232.53 % -1.02
Price to Sales 2.39 16.56 1353.49 %
Enterprise Value to EBITDA Multiple -0.326 -0.216 -787.45 %


ATRA - Profitability Highlights

Profitability Analysis

   Strong Return On Capital Employed of 292.50
   Company Earning excess return
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Steady Growth in EPS for last four quarters
   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 2.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   Negative Net Margin MRQ
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 0 0 0 % 0
Return On Asset -109.12 -175.37 -189.15 % -19.21
Net Profit Margin -687.41 -6390.31 -1679.45 % -116.07
Operating Profit Margin -665.12 -6419.70 -1354.91 % -114.22
EBITDA Margin -649.52 -6282.89 -1718.64 % -114.22


Highlights
Market Cap85495.36 K
Enterprise Value71833.36 K
Price/Book TTM-2.30
Outstanding Share120416 K
Float/ Outstanding Share76.90%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score2.00
Altman Z Score-22.51
Sloan Ratio-0.549
Peter Lynch Fair Value0


ATRA - Growth Highlights

Growth Analysis

   Short term positive trend in total sale and net profit
   YoY Net Margin Jump by 1679.45%
   Quarterly sales in last 5 years is trending up
   Tsr Growth Index - Very Poor Score of 5.00
   Companies' sales dropped by 92.86 % from last year
   Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 33911.00 K 92.86 % 543.39 %
Gross Profit 26151.00 K 100.49 % 2223.44 %
EBITDA -220260.00 K 29.93 % 39.99 %
Net Profit -233107.00 K 27.13 % 47.47 %
EPS -2.04 22.43 % NA


ATRA - Stability Highlights

Stability Analysis

   Debt to equity ratio has decreased and is lowest in last five years
   Tsr Stability Index - Very Poor Score of 9.38
   Altman Z Score of -22.54 suggest high risk
   Company is unable to generate enough free cash to support the business.
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio -0.123 -213.95 % 0
Cash Ratio 0.364 -88.18 %
Quick Ratio 0.648 -82.58 % 0.500
Shareholders Equity -59.96 -278.21 %
Debt to EBITDA -0.0427 31.28 %


Historical Valuation Ratios of Atara Biotherapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Atara Biotherapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Atara Biotherapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Atara Biotherapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)